Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - foscarnet sodium, quantity: 24 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - treatment of cytomegalovirus (cmv) retinitis in patients with the acquired immunodeficiency syndrome (aids). indications as at 11 november 1994: for treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids); and treatment of aciclovir resistant herpes simplex virus (hsv) infections (defined by clinical trial or in-vitro resistance) in immunocompromised patients with human immunodeficiency virus (hiv) infection. note: the indication for treatment of aciclovir resistant hsv infections in immunocompromised patients with hiv infections is based primarily on the results of one open label comparative study. this was of patients with hiv infections and herpetic lesions unresponsive to aciclovir administered intravenously for 10 days or more and in-vitro documented resistance to aciclovir. eight patients were randomised to foscarnet (40mg/kg iv given eight hourly) and 6 were randomised to vidarabine 15mg/kg iv daily. the results showed a significant difference in favour o

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tramadol hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: water for injections; sodium acetate - tramal solution for injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tramadol hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium acetate; water for injections - tramal solution for injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cisatracurium besilate, quantity: 6.7 mg/ml (equivalent: cisatracurium, qty 5 mg/ml) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - nimbex injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cisatracurium besilate, quantity: 2.68 mg/ml (equivalent: cisatracurium, qty 2 mg/ml) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - other conditions: protect from light. nimbex injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cisatracurium besilate, quantity: 2.68 mg/ml (equivalent: cisatracurium, qty 2 mg/ml) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - nimbex injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as adjunct to general anaesthesia, or sedation in the intensive care unit.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - antineoplastic chemotherapy: methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy: in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box): methotrexate may be of value in the symptomatic control o

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - antineoplastic chemotherapy: methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy: in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box): methotrexate may be of value in the symptomatic control o